In the last trading session, the stock price of Infinity Pharmaceuticals Inc (NASDAQ:INFI) declined more than 1% to close the day at $1.80. The decline came at a share volume of 967,480 compared to average share volume of 2.2 million. Last month, the firm posted Phase 1 translational and clinical data for IPI-549.
The report from the recently concluded monotherapy dose-escalation component of Infinity’s Phase 1/1b trial showcased that IPI-549 dosed QD was clinically active and well tolerated. Among 18 subjects assessable for activity, there was a 44% clinical benefit rate, mentioned as subjects who had continued on treatment for minimum 16 weeks, counting one partial response in a subject with advanced peritoneal mesothelioma.
In addition, initial translational report from patient blood samples showcased that IPI-549 treatment leads in immune stimulation, with preliminary proof of biological activity associating with clinical benefit. The abstract describing the data was showcased in an oral presentation at the 2017 SITC Annual Meeting that took place from November 10 to November 12. IPI-549 is considered to be the single selective PI3K-gamma inhibitor in clinical advancement
David Hong, M.D. expressed that as the majority of subjects treated with IPI-549 monotherapy suffered with advanced types of cancer and received numerous treatments prior to enrollment in this trial, it’s extremely encouraging that 44% of subjects remained on treatment for minimum 16 weeks, including a subject with a partial response who remained on treatment for more than a year and continues on trial.
There is a considerable requirement for better treatment alternatives for patients, particularly for patients who fail to respond to, or advance resistance to, current immunotherapies and for different types of cancer where there is confined benefit from therapy with checkpoint inhibitors. Infinity is assessing IPI-549 as a monotherapy as well as in combination with Opdivo®, in a Phase 1/1b trial in around 200 subjects with advanced solid tumors.